Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study.

Next Previous
Trial Profile

Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Atenolol; Doxazosin; Hydrochlorothiazide
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Acronyms CONFIRM
  • Sponsors Daiichi Sankyo Inc

Most Recent Events

  • 30 Mar 2012 Actual patient number is 114 according to ClinicalTrials.gov.
  • 22 Feb 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
  • 22 Feb 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top